CI

At a glance

ClinicalIndex Comparison Record
N/AActive· 108 enrolled
Drug / intervention
DexCom G6device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05360056
NCT05360056N/AActive

Effect of Continuous Glucose Monitoring Following Hospital Discharge of Patients With Type 2 Diabetes

Kathleen Dungan·interventional·Posted May 4, 2022·Updated Apr 29, 2026

In Brief

A clinical study evaluating DexCom G6 for Type 2 Diabetes. Active but no longer recruiting, targeting 108 participants across 1 site.

Detailed Summary

In this 12-week prospective observational cohort study, hospitalized insulin-requiring patients with T2D will receive a Dexcom continuous glucose monitor (CGM) to wear post-hospital discharge. Patients will complete surveys assessing patient-reported outcomes prior to CGM use and following completion of the study. CGM data will be captured by the patient smartphone app and analyzed. Patients will receive personalized CGM targets and alerts for hyperglycemia and hypoglycemia. Customized reports/ decision support will be sent to the usual diabetes provider. The initial observational cohort study design will be followed by an extension phase of 12 weeks in which data on continuation of use and glucose control will be collected but no further reports will be communicated to providers.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes
CountriesUnited States
CollaboratorsDexCom, Inc.

Timeline

N/AActiveOverdue
2023202420252026
First PostedMay 4, 2022
Enrollment StartApr 26, 2022
Primary CompletionAug 31, 2024
Study CompletionJul 1, 2026
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 4.2 years ago

Interventions

DexCom G6device

Wearable continuous glucose monitor